Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Atossa Genetics Inc (NASDAQ: ATOS).

Full DD Report for ATOS

You must become a subscriber to view this report.


Recent News from (NASDAQ: ATOS)

Atossa Genetics' (ATOS) Corporate Conference Call Transcript
Atossa Genetics (ATOS) Corporate Conference Call May 16, 2018 04:30 PM ET Executives John Marco - IR Steven Quay - CEO Kyle Guse - CFO Presentation Operator Good afternoon and welcome to the Atossa Genetics conference call to discuss the company's business. All particip...
Source: SeekingAlpha
Date: May, 16 2018 22:59
Atossa Genetics Receives Positive Interim Safety Review from Independent Safety Committee in Phase 1 Topical Endoxifen Dose Escalation Study in Men
SEATTLE, May 15, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announce...
Source: GlobeNewswire
Date: May, 15 2018 08:00
Atossa Genetics To Host Corporate Conference Call Wednesday, May 16, 2018 at 4:30pm EDT
SEATTLE, May 14, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announce...
Source: GlobeNewswire
Date: May, 14 2018 16:24
Atossa Genetics Announces First Quarter 2018 Financial Results And Provides Company Update
SEATTLE, May 14, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced First Quarter ended March 31, 2018 financial results a...
Source: GlobeNewswire
Date: May, 14 2018 08:00
Atossa Genetics Supports National Women's Health Week Lead by U.S. Department of Health and Human Services' Office on Women's Health
SEATTLE, May 11, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announce...
Source: GlobeNewswire
Date: May, 11 2018 08:00
Atossa Genetics Regains NASDAQ Compliance
SEATTLE, May 08, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announce...
Source: GlobeNewswire
Date: May, 08 2018 08:00
Atossa Genetics Reminds Investors of Today's Deadline to be a Shareholder of Record
- To be a shareholder of record, investors are advised to own Atossa stock  by 4:00 PM ET, Monday, May 7, 2018 to account for two-day settlement - Record date set as May 9, 2018 SEATTLE, May 07, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (ATOS) (“Atossa”...
Source: GlobeNewswire
Date: May, 07 2018 08:15
Atossa files for $25M rights offering
Atossa Genetics (NASDAQ: ATOS ) has filed a prospectus for subscription rights to purchase up to 25K Units at $1,000 per Unit. More news on: Atossa Genetics, Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 04 2018 08:37
Atossa Genetics Forms Strategic Advisory Board to Accelerate Growth
SEATTLE, May 03, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announce...
Source: GlobeNewswire
Date: May, 03 2018 08:15
Today's Research Reports on Stocks to Watch: Atossa Genetics and SteadyMed
NEW YORK, NY / ACCESSWIRE / May 1, 2018 / Pharma stocks Atossa Genetics and SteadyMed were seeing big gains in Monday trading after each company announced big news. Atossa has received approval from the Swedish Medical Products Agency (MPA) to conduct a Phase 2 Study of its Endoxifen, an inv...
Source: ACCESSWIRE IA
Date: May, 01 2018 08:10

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-162.1712.27032.352.1769,222
2018-08-152.212.1822.26022.0652181,161
2018-08-142.252.232.2972.2369,290
2018-08-132.262.2512.302.2520,730
2018-08-102.262.28852.3692.2628,783

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1616,70223,76270.2887Short
2018-08-1537,04267,78854.6439Short
2018-08-1413,93622,95760.7048Short
2018-08-135,5858,91162.6753Short
2018-08-102,6225,28249.6403Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ATOS.


About Atossa Genetics Inc (NASDAQ: ATOS)

Logo for Atossa Genetics Inc (NASDAQ: ATOS)

Not available

 

Contact Information

     

     

    Current Share Structure

    • Market Cap: $10,183,496 - 05/14/2018
    • Authorized: 75,000,000 - 05/01/2018
    • Issue and Outstanding: 2,651,952 - 05/01/2018

     


    Recent Filings from (NASDAQ: ATOS)

    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 17 2018
    Free Writing Prospectus
    Filing Type: FWPFiling Source: edgar
    Filing Date: May, 16 2018
    Quarterly report with a continuing view of a company's financial position
    Filing Type: 10-QFiling Source: edgar
    Filing Date: May, 14 2018
    Prospectus filed under Rule 424(b)(4)
    Filing Type: 424B4Filing Source: edgar
    Filing Date: May, 10 2018
    Amendment to general form for registration of securities under the Securities Act of 1933
    Filing Type: S-1/AFiling Source: edgar
    Filing Date: May, 03 2018
    Statement of beneficial ownership of common stock by certain persons
    Filing Type: SC 13GFiling Source: edgar
    Filing Date: April, 27 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: April, 23 2018
    Amendment to general form for registration of securities under the Securities Act of 1933
    Filing Type: S-1/AFiling Source: edgar
    Filing Date: April, 23 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: April, 17 2018
    Additional proxy soliciting materials - definitive
    Filing Type: DEFA14AFiling Source: edgar
    Filing Date: April, 16 2018

     

     


    Daily Technical Chart for (NASDAQ: ATOS)

    Daily Technical Chart for (NASDAQ: ATOS)


    Stay tuned for daily updates and more on (NASDAQ: ATOS)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: ATOS)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ATOS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ATOS and does not buy, sell, or trade any shares of ATOS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/